Home
Live Updates
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting : comparemela.com
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy...
Related Keywords
Chicago ,
Illinois ,
United States ,
Mccormick Place ,
American ,
Theodore Jenkins ,
Leslyem Heisler ,
Kyle Evans ,
Charu Aggarwal ,
Company Nasdaq ,
Business Development ,
Exchange Commission ,
American Society Of Clinical Oncology ,
Perelman School Of Medicine ,
Drug Administration ,
University Of Pennsylvania ,
Mccormick Place Convention Center ,
Candel Therapeutics Inc ,
Clinical Oncology ,
Annual Meeting ,
Associate Professor ,
Lung Cancer Excellence ,
Perelman School ,
Co Principal Investigator ,
Paul Peter Tak ,
Chief Executive Officer ,
Track Designation ,
Presentation Title ,
Poster Session ,
Lung Cancer ,
Non Small Cell Metastatic ,
Fast Track Designation ,
Special Protocol Assessment ,
Orphan Drug Designation ,
Discovery Platform ,
Private Securities Litigation Reform Act ,
Investor Relations ,
comparemela.com © 2020. All Rights Reserved.